-
Mashup Score: 0Social Robotics Show Potential in Pediatric Cancer Patients During Hospitalization - Oncology Nurse Advisor - 5 day(s) ago
Researchers describe the results of using social robotics as an adjuvant therapy for hospitalized pediatric patients with cancer.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Leo Mascarenhas named director of Pediatric Hematology & Oncology at Cedars-Sinai Guerin Children’s - The Cancer Letter - 1 month(s) ago
Leo Mascarenhas was named director of Pediatric Hematology & Oncology at Cedars-Sinai Guerin Children’s and medical director of the Sarcoma Program at Cedars-Sinai Cancer Center. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet-
Leo Mascarenhas (@mascarleo) named director of Pediatric Hematology & Oncology at @GuerinChildrens. #PedOnc https://t.co/1mJBdVDcvL https://t.co/PMdRUmR1yd
-
-
Mashup Score: 4
Stage III patients with favorable histology Wilms tumor and a combination of loss of heterozygosity of 1p or 16q and lymph node involvement were examined in an expanded Children’s Oncology Group coho…
Categories: General Medicine News, Onc News and JournalsTweet-
Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from @COGorg Studies AREN03B2 and AREN0532 https://t.co/Bxq6DAoyKe @OncoAlert #PedOnc https://t.co/rFXJ2medxt
-
-
Mashup Score: 0Rozlytrek Approved for Younger Patients With NTRK Gene Fusion-Positive Solid Tumors - 6 month(s) ago
The FDA has granted accelerated approval to Rozlytrek (entrectinib) for pediatric patients aged ≥1 month with solid tumors that have an NTRK gene fusion.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet-
The @us_fda has granted accelerated approval to Rozlytrek for pediatric patients 1 month of age and older with solid tumors... From @empr. https://t.co/AHQxG2NEPy #PedOnc
-
-
Mashup Score: 3The role of relative advantage for development of sequencing‐based diagnostics for pediatric cancer in low‐ and middle‐income countries - 6 month(s) ago
Efforts to address limitations in cancer diagnostics in low- and middle-income countries should follow an approach that avoids two extremes: unproductive attempts to require implementation of high-in…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New commentary | The role of relative advantage for development of sequencing-based diagnostics for pediatric cancer in low- and middle-income countries 🔗https://t.co/UZUmmNXN4b @oncoalert @UNCDeptMedicine @AbbyRosenbergMD #pedonc https://t.co/hxORQIOzTP
-
-
Mashup Score: 0First-Line Dabrafenib/Trametinib in Pediatric BRAF V600–Mutated Low-Grade Glioma - The ASCO Post - 7 month(s) ago
In a phase II trial reported in The New England Journal of Medicine, Eric Bouffet, MD, and colleagues found that the combination of dabrafenib and trametinib produced a higher objective response rate vs standard chemotherapy in the first-line treatment of pediatric patients with low-grade glioma and BRAF V600 mutations. In the open-label trial, 110 patients from sites in 20 countries were randomly assigned 2:1 between September 2018 and December 2020 to receive dabrafenib/trametinib (n = 73) or standard
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pediatric BRAF V600–Mutated Low-Grade Glioma: First-Line Therapy https://t.co/1eenkHnVH4 #btsm #glioma #oncology #pedonc
-
-
Mashup Score: 0FDA Approves Bosutinib for Pediatric Patients With Chronic Myelogenous Leukemia - The ASCO Post - 7 month(s) ago
On September 26, the U.S. Food and Drug Administration (FDA) approved bosutinib (Bosulif) for pediatric patients aged 1 year and older with chronic-phase, Philadelphia chromosome–positive chronic myelogenous leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. The FDA also approved a new capsule dosage form, available in 50-mg and 100-mg doses. Efficacy was evaluated in the BCHILD trial (ClinicalTrials.gov identifier NCT04258943), a mult icenter, nonrandomized, open-label
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA Approves Therapy for Pediatric CML https://t.co/EDgGxhdH4M #leusm #leukemia #pedonc @FDAOncology
-
-
Mashup Score: 0Decentralized Care Models Empower Equitable Pediatric Cancer Treatment - The ASCO Post - 7 month(s) ago
Childhood Cancer Awareness Month is recognized every September to help shine a light on the realities of pediatric cancer and raise awareness of the important work being done to make a difference for the children who are diagnosed with cancer. September 15 also marked the start of Hispanic Heritage Month. As a Latin-American physician who has spent more than 33 years in pediatric care, the intersection of these two campaigns holds significant import ance to my identity as a native of San Francisco and my
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Decentralized Care Models Empower Equitable Pediatric Cancer Treatment, by Norman J. Lacayo, MD https://t.co/XunPlLWrWd #pediatriccancer #pedonc @StanfordMed
-
-
Mashup Score: 0
There is some evidence to support the use of cannabis for symptom management in children with cancer, but there is a lack of evidence on the safety and efficacy of cannabinoids in this patient population, according to researchers.
Source: www.oncologynurseadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
There is some evidence to support the use of cannabis for symptom management in children with cancer, but there is a lack of evidence on the safety and efficacy of #cannabinoids in this patient population. From @AmericanCancer and @CancerTherAdvsr. https://t.co/olni981w62 #PedOnc
-
-
Mashup Score: 0
Dabrafenib plus trametinib can produce durable responses in pediatric patients with relapsed or refractory, BRAFV600-mutant high-grade glioma, a phase 2 trial suggests.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of dabrafenib and trametinib can produce durable responses in pediatric patients with R/R, BRAFV600-mutant high-grade #glioma. Published in @JCO_ASCO. https://t.co/1CuOGji3V0 #PedOnc #BrainCancer
-
A recent pilot study investigated the potential of social robotics as an adjuvant therapy during hospitalization for pediatric patients with cancer. https://t.co/d1DG4gy3pz #PedOnc